RU2019108824A - Соединения для лечения заболеваний, связанных с дисфункцией митохондрий - Google Patents
Соединения для лечения заболеваний, связанных с дисфункцией митохондрий Download PDFInfo
- Publication number
- RU2019108824A RU2019108824A RU2019108824A RU2019108824A RU2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A
- Authority
- RU
- Russia
- Prior art keywords
- group
- carbon atoms
- compound
- pharmaceutically acceptable
- hydrate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 23
- 230000004065 mitochondrial dysfunction Effects 0.000 title claims 12
- 201000010099 disease Diseases 0.000 title claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 11
- 238000011282 treatment Methods 0.000 title claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229920002477 rna polymer Polymers 0.000 claims 5
- 102000053602 DNA Human genes 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 4
- 125000003147 glycosyl group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical group OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0 | 2016-08-30 | ||
| EP16306094.0A EP3290039B1 (en) | 2016-08-30 | 2016-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
| PCT/EP2017/071812 WO2018041919A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019108824A true RU2019108824A (ru) | 2020-10-01 |
| RU2019108824A3 RU2019108824A3 (https=) | 2020-12-31 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019108824A RU2019108824A (ru) | 2016-08-30 | 2017-08-30 | Соединения для лечения заболеваний, связанных с дисфункцией митохондрий |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (https=) |
| EP (2) | EP3290039B1 (https=) |
| JP (1) | JP7065854B2 (https=) |
| KR (1) | KR20200011927A (https=) |
| CN (1) | CN110035758B (https=) |
| AU (1) | AU2017317651B2 (https=) |
| BR (1) | BR112019004236A2 (https=) |
| CA (1) | CA3034694A1 (https=) |
| ES (1) | ES2800917T3 (https=) |
| MA (1) | MA46099A (https=) |
| MX (1) | MX394782B (https=) |
| RU (1) | RU2019108824A (https=) |
| SG (1) | SG11201901689YA (https=) |
| WO (1) | WO2018041919A1 (https=) |
| ZA (1) | ZA201900997B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
| MA53258A (fr) * | 2018-03-07 | 2021-08-04 | Amabiotics | Composés pour le traitement de la maladie d'alzheimer |
| EP3906037A4 (en) * | 2019-01-29 | 2023-03-01 | Holobiome, Inc. | Methods and compositions for treating and preventing cns disorders and other conditions caused by gut microbial dysbiosis |
| EP4028014A1 (en) * | 2019-09-12 | 2022-07-20 | Stellate Therapeutics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
| CN116850191A (zh) * | 2023-06-16 | 2023-10-10 | 山东大学齐鲁医院 | 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用 |
| WO2026057085A1 (zh) * | 2024-09-15 | 2026-03-19 | 澳门科技大学 | Queuine在抗衰老中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| CA2217696A1 (en) * | 1995-04-25 | 1996-10-31 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417163D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
-
2016
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/en active Active
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
-
2017
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/en not_active Withdrawn
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 CA CA3034694A patent/CA3034694A1/en active Pending
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/en not_active Ceased
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 MX MX2019002369A patent/MX394782B/es unknown
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko not_active Abandoned
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018041919A1 (en) | 2018-03-08 |
| SG11201901689YA (en) | 2019-03-28 |
| US11684611B2 (en) | 2023-06-27 |
| JP7065854B2 (ja) | 2022-05-12 |
| MA46099A (fr) | 2019-07-10 |
| BR112019004236A2 (pt) | 2019-05-28 |
| MX394782B (es) | 2025-03-24 |
| AU2017317651A1 (en) | 2019-03-07 |
| CA3034694A1 (en) | 2018-03-08 |
| ZA201900997B (en) | 2020-05-27 |
| MX2019002369A (es) | 2019-11-07 |
| AU2017317651B2 (en) | 2022-12-15 |
| CN110035758B (zh) | 2023-06-16 |
| EP3290039A1 (en) | 2018-03-07 |
| JP2019526634A (ja) | 2019-09-19 |
| KR20200011927A (ko) | 2020-02-04 |
| RU2019108824A3 (https=) | 2020-12-31 |
| CN110035758A (zh) | 2019-07-19 |
| US10857135B2 (en) | 2020-12-08 |
| EP3290039B1 (en) | 2020-03-25 |
| US20210046056A1 (en) | 2021-02-18 |
| EP3506903A1 (en) | 2019-07-10 |
| US20190224174A1 (en) | 2019-07-25 |
| ES2800917T3 (es) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019108824A (ru) | Соединения для лечения заболеваний, связанных с дисфункцией митохондрий | |
| JP2019526634A5 (https=) | ||
| EP3581187B1 (en) | Skin pigmentation inhibitor | |
| KR950702994A (ko) | 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol) | |
| CN113164420B (zh) | 治疗组合物 | |
| BR112015026410A2 (pt) | derivados de dolastatina 10 e auristatinas | |
| CA2909160A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| RU2015148931A (ru) | Нутритивная композиция для улучшения функции мозга при фенилкетонурии | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2024037922A (ja) | 急性放射線症候群を予防又は処置するための組成物 | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| ES2395401T3 (es) | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer | |
| EP3064209B1 (en) | Composition comprising ginsenoside f2 for preventing or treating insulin resistance | |
| CN115335047A (zh) | 用于治疗血管脂肪瘤的组合物 | |
| RU2020132761A (ru) | Соединения для лечения болезни альцгеймера | |
| BR112017019753A2 (pt) | uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal | |
| KR101245328B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물을 포함하는 항암제 조성물 | |
| EP3130337B1 (en) | Combination of a urinary basifying agent and an uric acid crystallisation inhibitor for the treatment or prevention of renal lithiasis | |
| CN107848948A (zh) | 10‑羟基‑顺‑12‑十八碳烯酸烷基酯及其用途 | |
| RU2016115374A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| FI3503899T3 (fi) | Tuote ja menetelmä uridiinipitoisuuden lisäämiseksi plasmassa | |
| Corsetti et al. | Protect and counter-attack: Nutritional supplementation with essential amino acid ratios reduces doxorubicin–induced cardiotoxicity In Vivo and promote cancer cell death In Vitro | |
| RU2016115376A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| JP2648176B2 (ja) | 制癌剤 | |
| CZ26004U1 (cs) | Potravinový doplněk kompenzující nepříznivé účinky očkování |